I would like to comment on several points made in the FDA position paper.
It is our understanding that the death from staphylococcal disease which occurred in Florida was that of an infant who was not bathed with hexachlorophene. As a matter of fact, in that hospital there was marked conflict among the staff. Some had their babies bathed with hexachlorophene and others did not. The staff members themselves did not know which infants were or were not bathed with hexachlorophene in that particular nursery nor the manner in which they were bathed. However, I think that one thing is quite obvious and that is that there was a definite break in the nursery routine from a position of having all the babies bathed with hexachlorophene to a haphazard bathing with a resultant rise in staphylococcal disease.
I think the FDA's allusion to neuropathological changes in autopsy material from California have been adequately answered by Dr. Davis' studies which were presented at this meeting. I do think that a false impression is left with the reader if he only reads FDA's comments about this study in California. It is interesting to note that there were two representatives from the University of Cincinnati present at the conference and neither one of them mentioned any study about neuropathological changes in infants at the University of Cincinnati. However, obviously something was communicated to the FDA but I find it strange that no mention was made of the study during the discussion of neuropathology at the conference